Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Lager risico op abnormaal uterien bloedverlies met dabigatran ten opzichte van warfarine
jan 2017